Quantcast
Last updated on April 18, 2014 at 14:58 EDT

Latest Tau Stories

2014-03-13 23:22:39

BluMarble Gives Vivacity to the Term “Repurpose,” Transforming Vegas’ Bottles into Look Good/Feel Good Decor Las Vegas, NV (PRWEB) March 13, 2014 When it comes to repurposing, BluMarble has been busy rescuing used bottles from restaurants, bars, homes and events in the community and transforming them into beautiful accessories for all. While throwing back a drink in Las Vegas, it’s unlikely many give pause to where that bottle they’ve left empty ends up. Considering each patron...

2013-09-04 12:30:11

NEW YORK, Sept. 4, 2013 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the publication of a collaborative study in the peer-reviewed International Journal of Cell Biology that found tau oligomer trimers were specifically toxic to neuronal cultures. The study, titled "Trimeric tau is toxic to human neuronal cells at low...

2013-07-08 16:26:08

NEW YORK, July 8, 2013 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the company will present three posters during the Alzheimer's Association International Conference(®) (AAIC) to be held July 13 - 18, 2013, in Boston, MA at the Boston Convention & Exhibition Center. The posters will highlight Oligomerix's programs,...

2012-10-30 11:26:21

MONTE CARLO, Monaco, October 30, 2012 /PRNewswire/ -- The time for Tau is now as Phase 3 clinical trials get under way with a second-generation Tau Aggregation Inhibitor (TAI) aimed at halting the progression of Alzheimer's TauRx Therapeutics Ltd announced today the initiation of two global Phase 3 clinical trials in mild to moderate Alzheimer's disease. These landmark studies could provide the first definitive data on a...

2012-04-23 02:28:11

NEW YORK, April 23, 2012 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease and related neurodegenerative disorders, announced today the completion of approximately $2 million in Series A financing, which includes both issuance of new convertible preferred shares and debt conversion. Wheatley MedTech Partners, L.P., Wheatley New York Partners LP and Durand Venture Associates, LLC were the lead...

2012-04-03 08:47:33

Immunotherapy with the antibody bapineuzumab in patients with mild to moderate Alzheimer disease resulted in decreases in a cerebrospinal fluid biomarker, which may indicate downstream effects on the degenerative process, according to a report published Online First by Archives of Neurology, a JAMA Network publication. Alzheimer disease (AD) is a progressive neurodegenerative disease characterized by, among other things, deposits of extracellular β-amyloid (Αβ)...

2012-03-21 00:34:44

New research in humans published today reveals that the so-called FKBP52 protein may prevent the Tau protein from turning pathogenic. This may prove significant for the development of new Alzheimer's drugs and for detecting the disease before the onset of clinical symptoms. A study published online today in the Journal of Alzheimer's Disease, for the first time demonstrates that the FKBP52 protein, discovered by Prof. Etienne BAULIEU twenty years ago, may prevent hyperphosphorylation of...

2012-03-15 05:40:15

(Ivanhoe Newswire) A new study shows that a new drug, called epothilone D (EpoD) is preventing neurological damage and improving cognitive performance in a mouse model of Alzheimer's disease (AD). Investigators from the Perelman School of Medicine at the University of Pennsylvania, led by first author Bin Zhang, MD, PhD, senior research investigator, and senior author Kurt R. Brunden, PhD, Director of Drug Discovery at the Center for Neurodegenerative Disease Research (CNDR), administered...

2012-03-09 08:00:00

GAITHERSBURG, Md., March 9, 2012 /PRNewswire-USNewswire/ -- Sigma-Tau Pharmaceuticals, Inc.'s Board of Directors today announced the appointment of Dave Lemus as Chief Operating Officer of Sigma-Tau Pharmaceuticals, Inc., following the resignation of his predecessor, Gregg Lapointe, whose duties Mr. Lemus will now assume with immediate effect. Additionally, the Board of Directors announced the approval of a new organizational structure within Sigma-Tau Pharmaceuticals, Inc., which affirms...

2012-02-03 09:18:50

Researchers tease out toxic role of tau oligomers One of the most distinctive signs of the development of Alzheimer's disease is a change in the behavior of a protein that neuroscientists call tau. In normal brains, tau is present in individual units essential to neuron health. In the cells of Alzheimer's brains, by contrast, tau proteins aggregate into twisted structures known as "neurofibrillary tangles." These tangles are considered a hallmark of the disease, but their precise role in...


Latest Tau Reference Libraries

3_70a675becb9f53d969ff4c22b8070e762
2004-10-19 04:45:40

Tau Ceti -- Tau Ceti is a star commonly used by science fiction authors since it is similar to the Sun, being of similar mass and similar spectral type as well as being relatively close to us. However, Tau Ceti is a "metal-deficient" star and therefore extremely unlikely to have rocky planets around it. It can be seen with the unaided eye as a faint star in the constellation of Cetus. ----- Click here to learn more on this topic from eLibrary:

More Articles (1 articles) »